Table of Contents

Executive Summary

ZX Market Snapshot: January, 2022:

  • ZX received 163% more asks than bids in January, marking the tenth consecutive month that the ZX orderbook skewed to the sellside.
  • January transactions priced from a 21.9% discount to a 28.8% premium to November average reported holding values.

Reported Holdings: Quarter Ending November 30th, 2021

  • This quarter reporting holders marked up their private portfolios 6.9% with an average mark-up of 3.5%. The period saw a 1:1 advance-decline ratio.
  • Sentiment up:
  • Sentiment down:

Heat Map: November 30th, 2021 Reporting Period

6.9%

Appreciation/Depreciation of All Reported Holdings1

3.5%

Average Mark-Up/Mark-Down Across All Reported Holdings2
Color Genomics
118.3%
Rad Power
98.7%
Tory Burch
87.4%
Nuro
59.7%
ABL Space
51.0%
SpaceX
30.0%
SiMa ai
27.4%
Rapyd
26.6%
Nubank
22.1%
Bytedance
19.4%
Atom Tickets
18.6%
SambaNova
11.1%
Astranis
10.9%
Fanatics
9.5%
FLEXE
8.7%
SnapDeal
7.0%
Epic Games
6.2%
Signifyd
6.1%
Starry
4.8%
Diamond Foundry
4.7%
Databricks
2.3%
Unqork
1.7%
Goop
1.6%
Tempus Labs
1.2%
EQRx
0.8%
Stripe
0.4%
Aledade
0.0%
Algolia
0.0%
Ankyra
0.0%
Astera Labs
0.0%
BETA Technologies
0.0%
Blink Health
0.0%
Bolt Threads
0.0%
Boundless Bio
0.0%
Bowery
0.0%
Caris
0.0%
Cava
0.0%
Celonis
0.0%
Checkr
0.0%
Chime
0.0%
Conformal Medical
0.0%
Deep Genomics
0.0%
dMed
0.0%
Druva
0.0%
Element Bio
0.0%
Enevate
0.0%
Evozyne
0.0%
goPuff
0.0%
GupShup
0.0%
HaulHub
0.0%
Heal
0.0%
Inscripta
0.0%
Insitro
0.0%
Intarcia Therapeutics
0.0%
Kardium
0.0%
Laronde
0.0%
MasterClass
0.0%
MOD Pizza
0.0%
Pine Labs
0.0%
PsiQuantum
0.0%
Rappi
0.0%
Reddit
0.0%
Redwood Materials
0.0%
RefleXion Medical
0.0%
Relativity Space
0.0%
Resilience
0.0%
Seismic
0.0%
ServiceTitan
0.0%
Sila Nano
0.0%
Skyhawk
0.0%
Sonoma Bio
0.0%
Tenstorrent
0.0%
Thriveworks
0.0%
T-Knife
0.0%
Treeline Bio
0.0%
ValenzaBio
0.0%
Verily
0.0%
Waymo
0.0%
Wugen
0.0%
Xsight Labs
0.0%
Aristea Therapeutics
-0.2%
JUUL
-0.4%
AgBiome
-1.2%
Convoy
-2.4%
Delhivery
-2.9%
Farmers Business Network
-4.1%
FlixBus
-4.1%
Instacart
-8.1%
Ant Financial
-8.8%
Dataminr
-10.3%
ElevateBio
-10.9%
Honor Tech
-12.7%
Sonder
-13.2%
Freenome
-16.1%
BYJU's
-16.7%
Scorpion Therapeutics
-21.9%
Castle Creek
-22.2%
Dragonfly Therapeutics
-22.2%
Faraday Pharma
-22.2%
PrognomIQ
-22.6%
D2iQ
-32.7%
Lime
-36.4%
Aurora Innovation
-51.9%

1 Dollar-weighted return on all reported holdings
2 Equal-weighted mark-up or mark-down across all reported holdings

Analysis

Positive Trend Reversal3 (# = consecutive prior qtrs marked down or flat)
Negative Trend Reversal4 (# = consecutive prior qtrs marked up or flat)
Positive Trend Reversal3 (# = consecutive prior qtrs marked down or flat)
JUUL
9
Bytedance
3
SnapDeal
2
Tory Burch
2
Negative Trend Reversal4 (# = consecutive prior qtrs marked up or flat)
Sonder
6
Castle Creek, Dataminr
5
Faraday Pharma
5
Epic Games, Freenome, Instacart
4

3 Positive Trend Reversal reflects an individual holding marked up after consecutive quarterly periods marked down or flat
4 Negative Trend Reversal reflects an individual holding marked down after consecutive quarterly periods marked up or flat

Highest Variance in Reported Marks5
CompanyNormalized Std Dev5$ Weighted AvgMaxMin
Intarcia Therapeutics4.72$0.78$18.17$0.00
Epic Games.28$1014.81$1295.10$719.90
Ant Financial.25$2.08$6.43$2.02
PsiQuantum.12$23.42$26.23$20.45
Bytedance.10$136.87$168.10$130.52

5 Normalized Standard Deviation is used to express the measure of spread across reported marks and allows for comparison between companies independent of their price per share based on a dollar-weighted average.

ZX Firm Bids at Greatest Premium to Latest Reported Median Holding Value6
Epic Games
+66.7%
ZX Firm Offers at Greatest Discount to Latest Reported Median Holding Value6
There were no ZX Firm Offers at a discount to November's median holding values

6 Premium and Discount agnostic to share class

ZX Market Snapshot: January, 2022

ZX received 163% more asks than bids in January, marking the tenth consecutive month that the ZX orderbook skewed to the sellside. January transactions priced from a 21.9% discount to a 28.8% premium to November average reported holding values.

January saw an Epic Games ZX Firm Bid posted at a 66.7% premium to November’s median holding value. There were no ZX Firm Offers at a discount to November’s median holding values.

Reported Holdings Commentary: Quarter Ending November 30th, 2021

This quarter reporting holders marked up their private portfolios 6.9% with an average mark-up of 3.5%. The period saw a 1:1 advance-decline ratio.

Color Genomics saw the largest mark-up this reporting period, with Rad Power, Tory Burch and Nuro rounding out the largest gainers. Aurora Innovation saw the largest mark-down this reporting period, while Lime, D2iQ and PrognomIQ saw the next largest markdowns.

JUUL saw its first positive reversal in nine quarters. Sonder saw its first negative reversal in six quarters while Dataminr, Castle Creek and Faraday Pharma saw their first negative reversals in five quarters.

Intarcia Therapeutics($0.00-$18.17) saw the highest share price variance across funds.

What is a ZX Firm Order?

ZX Firm Orders are unique to ZX. A ZX Firm Order (Offer or Bid) is a form of contract accepted on ZX, that allows a buyer or seller to contractually commit themselves to trading at the terms of an order ticket should a bona fide counterparty be presented, or pay a fee set to 10% of the notional value of the transaction should they fail to transact. Zanbato developed the concept of a Firm Order for private stock trading to solve for frequent frustration that parties often hold themselves out as buyers or sellers, but then pull out of transactions when counterparties are presented.

Disclaimer

This report is based on data reported by 200+ funds. Many holders of private company shares do not report their holding values and are thus not included in this report’s dataset. Further, many venture-backed private companies are not held by any reporting funds and are thus not included in this report. As such, this report should not be construed as providing a complete picture of shareholder sentiment or venture-backed private company performance. This report does not constitute investment advice or a "research report" as defined by FINRA Rules.

Zanbato Securities LLC (“Zanbato”) prepares and disseminates market information about venture-backed private company securities, and the current bids and offers for those securities listed on the ATS operated by Zanbato (“ZX”). The information provided in this report has been prepared by sales, trading, or other non-research functions. Pricing indications and macro commentary are provided for factual information purposes only. This report is not intended to assess the individual merits of a particular investment or strategy, does not constitute a recommendation to buy or sell any financial instrument or to participate in any trading strategy and should not be construed as such. This report does not constitute investment advice. Certain information in this report has been obtained from third party sources and, while such information was believed by Zanbato to be reliable, it has not been independently verified by Zanbato and Zanbato shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with any use of, or reliance on, such third party information. Furthermore, the information contained in this report may not be current due to, among other things, changes in the financial markets or economic environment. Zanbato does not, and has no obligation to, update any such information contained in this report. Any prices or quotations contained herein are indicative only, do not represent firm quotes as to either price or size and should not be used for valuation purposes.

yukacon_arrow_up_right